Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Antibiotic for the treatment of bacterial vaginosis.
One applicator full intravaginally at bedtime for 7 consecutive days.
In patients for whom a shorter treatment course is desirable, a 3 day regimen has been shown to be effective.
Safety and efficacy in paediatric patients have not been established (see section 4.4).
No clinical studies have been conducted in populations older than 60.
There are no reports of overdose with clindamycin. Vaginally applied clindamycin phosphate vaginal cream 2% can be absorbed in sufficient amounts to produce systemic effects.
In the event of overdosage, general symptomatic and supportive measures are indicated as required.
Accidental oral intake can lead to effects comparable with those of therapeutic concentrations of orally administered clindamycin.
2 years.
Do not store above 25°C. Do not freeze.
Laminate tube (consisting of LMDPE and aluminium foil) with polypropylene cap containing 7.8 g, 20 g or 40 g cream, packed in cardboard carton, together with a leaflet.
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
